About Fractyl Health, Inc. Common Stock
https://fractyl.comFractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
CEO
Harith Rajagopalan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:12.14M
Value:$24.4M
SILVERARC CAPITAL MANAGEMENT, LLC
Shares:10.6M
Value:$21.31M
ALYESKA INVESTMENT GROUP, L.P.
Shares:5.65M
Value:$11.35M
Summary
Showing Top 3 of 79
About Fractyl Health, Inc. Common Stock
https://fractyl.comFractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $22.4M ▼ | $-45.6M ▼ | 0% | $-0.71 ▼ | $-45.31M ▼ |
| Q2-2025 | $0 | $26.08M ▲ | $-27.89M ▼ | 0% | $-0.57 ▼ | $-25.81M ▼ |
| Q1-2025 | $0 ▼ | $24.76M ▼ | $-23.73M ▲ | 0% ▲ | $-0.49 ▲ | $-24.47M ▲ |
| Q4-2024 | $3K ▼ | $25.21M ▲ | $-24.97M ▼ | -832.33K% ▼ | $-0.51 ▼ | $-24.99M ▼ |
| Q3-2024 | $14K | $23.8M | $-23.17M | -165.52K% | $-0.48 | $-23.59M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $77.66M ▲ | $114.27M ▲ | $117.45M ▲ | $-3.18M ▲ |
| Q2-2025 | $22.29M ▼ | $62.01M ▼ | $80.22M ▲ | $-18.21M ▼ |
| Q1-2025 | $42.11M ▼ | $83.04M ▼ | $76.67M ▼ | $6.38M ▼ |
| Q4-2024 | $67.46M ▼ | $108.08M ▼ | $79.65M ▲ | $28.42M ▼ |
| Q3-2024 | $84.66M | $126.92M | $76.6M | $50.32M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-45.6M ▼ | $-22.71M ▼ | $-8K ▲ | $78.09M ▲ | $55.37M ▲ | $-22.72M ▼ |
| Q2-2025 | $-27.89M ▼ | $-21.2M ▲ | $-98K ▲ | $1.48M ▲ | $-19.82M ▲ | $-21.3M ▲ |
| Q1-2025 | $-23.73M ▲ | $-25.08M ▼ | $-448K ▼ | $171K ▲ | $-25.36M ▼ | $-25.53M ▼ |
| Q4-2024 | $-24.97M ▼ | $-17.03M ▲ | $-233K ▼ | $67K ▼ | $-17.2M ▲ | $-17.27M ▲ |
| Q3-2024 | $-23.17M | $-18.04M | $-213K | $162K | $-18.09M | $-18.25M |
CEO
Harith Rajagopalan
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:12.14M
Value:$24.4M
SILVERARC CAPITAL MANAGEMENT, LLC
Shares:10.6M
Value:$21.31M
ALYESKA INVESTMENT GROUP, L.P.
Shares:5.65M
Value:$11.35M
Summary
Showing Top 3 of 79